Patrick R. O'Neil - 02 Jan 2026 Form 4 Insider Report for IONIS PHARMACEUTICALS INC (IONS)

Reporting relationship: EVP CLO & General Counsel
Issuer ticker: IONS
Reported as of: 02 Jan 2026
Net transaction value: $0
SEC form: 4
Accepted by SEC: 06 Jan 2026, 17:35:13 UTC
Prior SEC filing: 08 Oct 2025
Next SEC filing: 20 Jan 2026
Source filing: View source filing
Reporting owner signature: Patrick R. O'Neil

Key filing fact

Patrick R. O'Neil filed Form 4 for IONIS PHARMACEUTICALS INC (IONS) on 06 Jan 2026.

Key facts

This page summarizes Patrick R. O'Neil's Form 4 filing for IONIS PHARMACEUTICALS INC (IONS).
1 reported transaction and 1 derivative row are listed below.
Accepted by SEC: 06 Jan 2026, 17:35.

Change

Previous filing in this sequence was filed on 08 Oct 2025.
Current net transaction value: $0.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reporting Owners (1)

CIK 0001564926 Primary reporting owner

O'NEIL PATRICK R.

Relationship: EVP CLO & General Counsel
Address: 2855 GAZELLE COURT, CARLSBAD
Signature: Patrick R. O'Neil
Signature date: 05 Jan 2026

Reported derivative securities

Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.

IONS transaction Derivative

Non-Qualified Stock Option (right to buy)

Award

Transaction value: $0
Shares: +19,350
Change %
Price: $0.000000
Shares after: 19,350
Date: 02 Jan 2026
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 19,350
Exercise price: $79.67
Footnotes: F1

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 1 footnote

Footnote F1

Grant on 01/02/2026 to reporting person of stock options under the Ionis Pharmaceuticals, Inc. Amended and Restated 2011 Equity Incentive Plan. Following this transaction, the option was exercisable as to 0 shares on 01/02/2026. 25% of the shares subject to the option will vest and become exercisable on 01/02/2027. Thereafter, the remaining shares subject to the option will vest and become exercisable in 36 equal monthly installments over the next 3 years.